Anebulo Pharmaceuticals, Inc. (ANEB) Stock Price & Analysis

Anebulo Pharmaceuticals, Inc. (ANEB) fell 7.95% to USD 0.36 as of September 8, 2026 at 06:56 UTC, according to Nexqual real-time market data.

ANEB last closed at USD 0.36; the session ranged USD 0.87–0.87 on volume of 100 shares. Market capitalization is —, with a 52-week range of USD 0–2.85 (PNK). Source: Nexqual, September 8, 2026 at 06:56 UTC.

Key Statistics (as of September 8, 2026 at 06:56 UTC)

Technical Analysis (ANEB)

Nexqual's technical model rates ANEB "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 06:56 UTC.

From Anebulo Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2025-09-29)

Key Strengths & Strategy (as disclosed to the SEC)

• Pediatric patients exposed to cannabis are at risk of serious and life-threatening outcomes including Central Nervous System ("CNS") depression, respiratory depression, seizures, and coma.
• The REMS typically includes risk minimization tools, medication guides, assessment plans, physician communication plans, and elements to ensure safe use, including restricted distribution methods, and patient registries.   The FDA reviews all NDAs submitted to ensure they are sufficiently complete for substantive review before it accepts them for filing.
• In addition, the FDA may require post-approval studies, including Phase 4 clinical studies, to further evaluate safety and effectiveness.
• FDA review and approval is generally required for post-approval changes to the manufacturing process and other changes to the approved product, including the addition of new indications and additional labeling claims.   Manufacturers and others involved in the manufacturing and distribution of approved products must register their establishments with the FDA and certain state agencies.

Partnerships

• Potential current competitors include Aelis Farma, which is developing a medication based on a pregnenolone derivative to treat cannabis use disorders in collaboration with Indivior PLC.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 06:56 UTC. This page is informational and not investment advice.